Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Graphite Bio Inc.
Headquarters: South San Francisco, CA, United States of America
Website: N/A
Year Founded: 2020
Status: Reverse-merged
BioCentury | Dec 31, 2024
Management Tracks
Casdin to succeed Cox at Epirium
Plus: van Tilburg takes the helm at Renovaro and updates from Medicilon, Applied, Neurocentrx and more
BioCentury | Oct 18, 2024
Management Tracks
Co-founders Mulvaney, Brennan return to BenevolentAI as CEO Moeller departs
Plus: Sage downsizes and updates from Xaira, DNA Script, Renovaro, Achieve, Adverum and more
BioCentury | Oct 15, 2024
Management Tracks
Rubin leaving Boundless as CFO, new CSOs for C4, Avacta and Commit
Plus: David Cameron named chair of Oxford-Harrington Rare Disease Centre’s advisory council, and updates from Twist, Boundless, Lucy and more
BioCentury | Apr 6, 2024
Discovery & Translation
Science spotlight: Three strategies for enhanced genome editing, plus Mapp’s Nipah virus mAb
BioCentury’s roundup of translational innovations
BioCentury | Dec 20, 2023
Data Byte
2023’s biotech reverse mergers
Half of the U.S.-listed biotechs that announced reverse mergers this year had been public for four years or less
BioCentury | Dec 19, 2023
Discovery & Translation
Next-gen gene editing at ASH
Non-Cas9 enzymes and strategies to improve ex vivo and in vivo engineering of hematopoietic cells are among the innovations
BioCentury | Dec 9, 2023
Regulation
Two sickle cell gene therapies enter U.S. market, but can both succeed?
FDA approves pair of sickle cell therapies with curative potential, but safety and pricing concerns cloud bluebird’s commercial path
BioCentury | Dec 9, 2023
Deals
Dec. 8 Quick Takes: Kamau debuts with rights to Graphite sickle cell asset
Plus: Spyre boosts balance sheet with $180M PIPE and Pfizer’s bispecific gains EU approval for multiple myeloma
BioCentury | Nov 16, 2023
Deals
Nov. 15 Quick Takes: Kite, Arcellx expand CAR T deal
Plus: Gilde closes new €740M fund and updates from RefleXion, NMD, Lenz-Graphite, Cytovale, T-Therapeutics, Vittoria, CorMedix
BioCentury | Oct 18, 2023
Management Tracks
eTheRNA names Sagaert CEO, Dekkers as chairman
Plus: Cyrus Harmon becomes CEO at Vilya, and updates from Epic Bio, Exscientia, Pliant, Cognito, Pattern
Items per page:
1 - 10 of 36